← Leaderboards
Vinay K Puduvalli
University Of Texas Md Anderson Can Ctr
$3,692,967
Attributed
$5,131,820
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $603.4K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,131,820 · 5
By mechanism
R01$3,883,795 · 2
K24$580,307 · 1
R21$563,685 · 1
P30$104,033 · 1
Top collaborators
- Deepa Sampath6 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Jasti S Rao$18,364,597
- Gilbert J. Cote$4,945,930
- Francis Ali-Osman$9,395,076
- Robert C Bast$38,086,401
- Bharat B Aggarwal$1,480,636
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsGliomaBrain NeoplasmsClinical TrialsCellsOperative Surgical ProceduresRadiation TherapyToxic EffectGrantMemberGlioblastomaFundingSerumResearch PersonnelRecurrenceTissuesBaseProgramsPathway InteractionsResistanceResponseHeterogeneityMalignant Neoplasm Of Brain
Grant awards (22)
05 Brain Cancer$24,692
P30 · FY2025 · CA · contact PI
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma$541,645
R01 · FY2024 · CA · contact PI
05 Brain Cancer$23,220
P30 · FY2024 · CA · contact PI
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma$568,351
R01 · FY2023 · CA · contact PI
05 Brain Cancer$18,707
P30 · FY2023 · CA · contact PI
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma$570,459
R01 · FY2022 · CA · contact PI
05 Brain Cancer$18,707
P30 · FY2022 · CA · contact PI
05 Brain Cancer$18,707
P30 · FY2021 · CA · contact PI
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma$560,714
R01 · FY2020 · CA · contact PI
Characterization of Onalespib, A novel long acting Hsp90 inhibitor, as a chemo and radiosensitizer in Adults with Newly Diagnosed Glioblastoma$33,147
R01 · FY2020 · CA · contact PI
Characterization of Onalespib, A novel long acting Hsp90 inhibitor, as a chemo and radiosensitizer in Adults with Newly Diagnosed Glioblastoma$603,390
R01 · FY2019 · CA · contact PI
Patient Oriented Research Program in Neuro-oncology$72,326
K24 · FY2015 · CA · contact PI
Patient Oriented Research Program in Neuro-oncology$180,537
K24 · FY2014 · CA · contact PI
Patient Oriented Research Program in Neuro-oncology$163,722
K24 · FY2013 · CA · contact PI
Patient Oriented Research Program in Neuro-oncology$163,722
K24 · FY2012 · CA · contact PI
Efficacy and toxicity of TRAIL against gliomas$181,692
R01 · FY2010 · CA · contact PI
Efficacy and toxicity of TRAIL against gliomas$181,692
R01 · FY2009 · CA · contact PI
Efficacy and toxicity of TRAIL against gliomas$181,692
R01 · FY2008 · CA · contact PI
Efficacy and toxicity of TRAIL against gliomas$227,115
R01 · FY2007 · CA · contact PI
Efficacy and toxicity of TRAIL against gliomas$233,898
R01 · FY2006 · CA · contact PI
Correlative trial of fenretinide against Glioblastomas$279,463
R21 · FY2003 · CA
Correlative trial of fenretinide against Glioblastomas$284,222
R21 · FY2002 · CA